Danaher (NYSE:DHR) had its target price boosted by Morgan Stanley from $103.00 to $110.00 in a note issued to investors on Wednesday. The brokerage currently has an “overweight” rating on the conglomerate’s stock. Morgan Stanley’s price target suggests a potential upside of 8.61% from the company’s previous close.
A number of other brokerages also recently weighed in on DHR. Cowen reiterated a “buy” rating and set a $110.00 price target on shares of Danaher in a report on Tuesday. Credit Suisse Group reiterated an “outperform” rating and set a $105.00 price target (up previously from $99.00) on shares of Danaher in a report on Wednesday. Stifel Nicolaus reiterated a “buy” rating and set a $110.00 price target on shares of Danaher in a report on Friday, January 19th. UBS Group began coverage on Danaher in a research note on Monday, January 22nd. They issued a “buy” rating and a $99.97 target price on the stock. Finally, Robert W. Baird restated a “buy” rating on shares of Danaher in a research note on Friday, January 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Danaher has an average rating of “Buy” and an average target price of $98.74.
Shares of Danaher (NYSE DHR) traded down $0.32 during trading on Wednesday, hitting $101.28. The stock had a trading volume of 3,261,268 shares, compared to its average volume of 2,380,000. Danaher has a 12 month low of $78.97 and a 12 month high of $104.82. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $70,450.00, a price-to-earnings ratio of 28.94, a PEG ratio of 2.25 and a beta of 1.03.
In other Danaher news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $93.33, for a total value of $3,534,407.10. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 12.20% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in DHR. GQG Partners LLC bought a new stake in shares of Danaher during the 2nd quarter worth about $101,000. Zions Bancorporation boosted its stake in shares of Danaher by 118.3% during the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after acquiring an additional 667 shares in the last quarter. Patten Group Inc. boosted its stake in shares of Danaher by 262.3% during the 3rd quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after acquiring an additional 3,497 shares in the last quarter. First Personal Financial Services boosted its stake in shares of Danaher by 128.9% during the 4th quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock worth $114,000 after acquiring an additional 691 shares in the last quarter. Finally, Monetary Management Group Inc. boosted its stake in shares of Danaher by 10.7% during the 2nd quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after acquiring an additional 150 shares in the last quarter. Institutional investors own 76.16% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by American Market News and is the sole property of of American Market News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/31/danaher-dhr-price-target-raised-to-110-00-at-morgan-stanley.html.
About Danaher
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
